Concord Biotech's March quarter profit up by 48%
By Ankur Chandra | Updated at: May 31, 2025 10:41 PM IST
Ahmedabad | May 30, 2025 – Concord Biotech Ltd (NSE: CONCORDBIO, BSE: 543960) announced the release of its strong financial performance for the quarter and financial year ended March 31, 2025.
Q4 & FY25 Financial Highlights (Consolidated)
| (₹ in Cr) | Q4 FY25 | Q4 FY24 | YoY% | FY25 | FY24 | YoY% |
|---|---|---|---|---|---|---|
| Revenue from Ops | 429.9 | 319.0 | +35% | 1,200.1 | 1,016.9 | +18% |
| EBITDA | 190.4 | 134.3 | +42% | 506.3 | 431.6 | +17% |
| EBITDA Margin (%) | 44.3% | 42.1% | +220 bps | 42.2% | 42.4% | -25 bps |
| PAT | 140.4 | 95.0 | +48% | 371.6 | 308.1 | +21% |
| PAT Margin (%) | 32.7% | 29.8% | +290 bps | 31.0% | 30.3% | +70 bps |
| EPS (₹) | 13.4 | 9.0 | — | 35.5 | 29.4 | — |
Segment-Wise Revenue Performance
- API Business:
- Revenue grew 37% YoY in Q4 and 14% in FY25 to ₹940.1 crore
- Continued strength in anti-infective and immunosuppressant portfolio
- Revenue jumped 26% YoY in Q4 and 38% in FY25 to ₹260 crore
- Domestic expansion and new product launches were key drivers
- Share in total revenue increased to 22% in FY25 from 19% in FY24
Geographic Revenue Mix
- Domestic: ₹661.8 crore in FY25, up 24% YoY
- Exports: ₹538.3 crore in FY25, up 12% YoY
- Domestic export revenue mix shifted slightly to 55:45 in FY25 from 53:47 in FY24
Operational & Strategic Developments
- Final USFDA approval for Teriflunomide tablets (7mg & 14mg) with a $402 million US market potential
- New formulation unit commissioned at Valthera, enhancing injectable manufacturing capabilities
- Palvella Therapeutics Inc. (rare genetic skin disease pipeline)
- CleanMax (renewable power for Dholka plant, reducing energy costs)
Regulatory Milestones
- Successfully completed inspections by USFDA, MFDS (Korea), SFDA (Saudi Arabia)
- Valthera Unit II awarded EU-GMP certification by HPRA (Ireland)
Management Commentary
Ankur Vaid, Joint MD & CEO, stated:
“Our revenue rose 35% YoY in Q4 and 18% for the full year, with even stronger growth in EBITDA and PAT. This reflects the strength of our business model and disciplined execution. The formulations business outperformed, backed by market expansion and product launches. Our new injectable plant, global regulatory approvals, and CDMO opportunities further strengthen our positioning for future growth.”
Balance Sheet Snapshot (As of March 31, 2025)
- Total Assets: ₹2,034.2 crore (vs ₹1,700.7 crore in FY24)
- Total Equity: ₹1,812.7 crore
- Cash and Cash Equivalents: ₹0.9 crore
- Net Cash from Operations: ₹244.5 crore
Strategic Outlook
The company has over 30 fermentation-based APIs and is present in more than 70 countries. It has over 100 approved formulation products. Included in its portfolio is Concord Biotech, which continues to strengthen its contract development and manufacturing organisation (CDMO) partnerships. The company expects its future growth to be supported by deeper penetration in regulated markets, innovation in R&D, and sustained operational efficiency.
The company’s future strategies include:
- Launch of injectables
- Leveraging fermentation leadership for CDMO growth
- Continued product expansion and in-licensing strategies
About the Company
Concord Biotech Ltd is an Indian company that specialises in biopharmaceutical research and development, as well as the manufacturing of active pharmaceutical ingredients. The company was founded in 2000 and is a global leader in niche therapeutic segments, including immunosuppressants, oncology, and anti-infectives.
Dividend: The company did not announce any dividend for FY25.
REF: https://www.bseindia.com/xml-data/corpfiling/AttachLive/f294d177-d40e-4b02-b999-cdaa5e026110.pdf
